Veracyte
Veracyte, Inc., a leading genomic diagnostics company headquartered in the United States, is at the forefront of transforming patient care through innovative solutions. Founded in 2013, Veracyte has made significant strides in the field of molecular diagnostics, particularly in oncology and pulmonary diseases. The company’s core offerings include advanced genomic tests that provide critical insights for accurate disease diagnosis and management, setting them apart in a competitive market. With a strong presence in the US and expanding operations globally, Veracyte has established itself as a trusted partner for healthcare providers. Notable achievements include the development of unique tests that enhance the diagnostic process, thereby improving patient outcomes. As a pioneer in the industry, Veracyte continues to lead the way in precision medicine, making significant contributions to the evolving landscape of genomic healthcare.
DitchCarbon Score
How does Veracyte's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Veracyte's score of 23 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Veracyte's reported carbon emissions
Veracyte, Inc., headquartered in the United States, currently does not have publicly available carbon emissions data for the most recent year. However, the company is committed to addressing climate change through various initiatives. While specific reduction targets have not been disclosed, Veracyte has made a commitment to near-term emissions reduction, indicating a proactive approach to sustainability within the healthcare sector. As part of its climate strategy, Veracyte is classified under the Healthcare Providers and Services and Healthcare Technology sectors, which are increasingly recognising the importance of reducing carbon footprints. Although the company has not set a net-zero target, its commitment to near-term reductions reflects an awareness of the industry's environmental impact. Veracyte's efforts align with broader industry trends, where companies are increasingly held accountable for their carbon emissions and are encouraged to adopt science-based targets. As the company continues to develop its climate commitments, stakeholders can expect further updates on its sustainability initiatives and emissions reduction strategies.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Veracyte is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
